Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 05, 2022 09:00 ET | Source: Lumos Pharma, Inc.

Lumos Pharma to Present at the H.C. Wainwright BIOCONNECT Virtual Conference

AUSTIN, Texas, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that the Company...
November 10, 2021 17:06 ET | Source: Lumos Pharma, Inc.

Lumos Pharma to Participate in Upcoming Investor Conferences

AUSTIN, Texas, Nov. 10, 2021 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that the Company...
November 03, 2021 16:01 ET | Source: Lumos Pharma, Inc.

Lumos Pharma Reports Third Quarter 2021 Financial Results and Provides Clinical Updates

Majority of OraGrowtH210 Trial sites are open with recent and imminent openings representing historically high enrollment sitesSix-month primary outcome data readout from OraGrowtH210 expected 2H 2023...
October 21, 2021 16:05 ET | Source: Lumos Pharma, Inc.

Lumos Pharma to Report Third Quarter 2021 Financial Results and Host Conference Call on November 3, 2021

AUSTIN, Texas, Oct. 21, 2021 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, today announced it will...
September 02, 2021 08:00 ET | Source: Lumos Pharma, Inc.

Lumos Pharma to Participate in September Investor Conferences

AUSTIN, Texas, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that the Company...
August 05, 2021 08:00 ET | Source: Lumos Pharma, Inc.

Lumos Pharma Reports Second Quarter 2021 Financial Results and Provides Clinical and Corporate Updates

• Lumos Pharma strengthens leadership team with promotion of John McKew, PhD to President, and addition of David B. Karpf, MD as Chief Medical Officer and Mark Bach, MD, PhD to Advisory Board •...
August 03, 2021 08:00 ET | Source: Lumos Pharma, Inc.

Lumos Pharma Announces Industry Veteran, David B. Karpf, MD, has Joined the Company as Chief Medical Officer

AUSTIN, Texas, Aug. 03, 2021 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, has announced that...
August 02, 2021 08:00 ET | Source: Lumos Pharma, Inc.

Lumos Pharma Announces the Promotion of COO and Chief Scientific Officer, John McKew, PhD, to President

AUSTIN, Texas, Aug. 02, 2021 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, has announced that current...
July 26, 2021 16:18 ET | Source: Lumos Pharma, Inc.

Lumos Pharma Appoints Pediatric Endocrinologist Experienced in Clinical Research and Pharmaceutical Development, Mark Bach, M.D., Ph.D., to Clinical Scientific Advisory Board

AUSTIN, Texas, July 26, 2021 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that Mark Bach,...
July 22, 2021 08:00 ET | Source: Lumos Pharma, Inc.

Lumos Pharma to Report Second Quarter 2021 Financial Results and Host Conference Call on August 5, 2021

AUSTIN, Texas, July 22, 2021 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, today announced it will...